188 related articles for article (PubMed ID: 33145606)
1. Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.
Rosenberg D; Avni T; Tsvetov G; Gafter-Gvili A; Diker-Cohen T
Osteoporos Int; 2021 Mar; 32(3):413-424. PubMed ID: 33145606
[TBL] [Abstract][Full Text] [Related]
2. Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis.
Diker-Cohen T; Rosenberg D; Avni T; Shepshelovich D; Tsvetov G; Gafter-Gvili A
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 31899506
[TBL] [Abstract][Full Text] [Related]
3. Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials.
Catton B; Surangiwala S; Towheed T
Int J Rheum Dis; 2021 Jul; 24(7):869-879. PubMed ID: 33793076
[TBL] [Abstract][Full Text] [Related]
4. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials.
Seeto AH; Abrahamsen B; Ebeling PR; Rodríguez AJ
J Bone Miner Res; 2021 Jan; 36(1):24-40. PubMed ID: 32780899
[TBL] [Abstract][Full Text] [Related]
6. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials.
Menshawy A; Mattar O; Abdulkarim A; Kasem S; Nasreldin N; Menshawy E; Mohammed S; Abdel-Maboud M; Gadelkarim M; El Ashal GG; Elgebaly AS
Support Care Cancer; 2018 Apr; 26(4):1029-1038. PubMed ID: 29387997
[TBL] [Abstract][Full Text] [Related]
7. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
Boquete-Castro A; Gómez-Moreno G; Calvo-Guirado JL; Aguilar-Salvatierra A; Delgado-Ruiz RA
Clin Oral Implants Res; 2016 Mar; 27(3):367-75. PubMed ID: 25639776
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.
Sun L; Yu S
Am J Clin Oncol; 2013 Aug; 36(4):399-403. PubMed ID: 22772430
[TBL] [Abstract][Full Text] [Related]
10. Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.
Chen F; Pu F
Oncol Res Treat; 2016; 39(7-8):453-9. PubMed ID: 27487236
[TBL] [Abstract][Full Text] [Related]
11. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
[TBL] [Abstract][Full Text] [Related]
12. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
Jiang L; Cui X; Ma H; Tang X
J Orthop Surg Res; 2021 Jun; 16(1):400. PubMed ID: 34158101
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
14. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
15. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.
Lv F; Cai X; Yang W; Gao L; Chen L; Wu J; Ji L
Bone; 2020 Jan; 130():115121. PubMed ID: 31678488
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
[TBL] [Abstract][Full Text] [Related]
17. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.
Peddi P; Lopez-Olivo MA; Pratt GF; Suarez-Almazor ME
Cancer Treat Rev; 2013 Feb; 39(1):97-104. PubMed ID: 22898302
[TBL] [Abstract][Full Text] [Related]
18. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
19. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
Wu J; Zhang Q; Yan G; Jin X
J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
[TBL] [Abstract][Full Text] [Related]
20. Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.
Rosenberg D; Avni T; Tsvetov G; Gafter-Gvili A; Diker-Cohen T
Osteoporos Int; 2021 Oct; 32(10):2131. PubMed ID: 34383097
[No Abstract] [Full Text] [Related]
[Next] [New Search]
